Holen Sie sich die Stockscreener-App
7.45
2.76%
0.20
Vorhandelsmarkt:
7.64
0.19
+2.55%
Cybin Inc Aktie (CYBN) Neueste Nachrichten
Cybin Inc. shares rise 3.20% intraday after receiving Australian approval for EMBRACE study. - AInvest
Cybin Receives Australian Approval for Phase 3 EMBRACE Study of CYB003 in Major Depressive Disorder Treatment - citybuzz -
Will earnings trigger a reversal in Cybin Inc.Quarterly Earnings Report & Verified Trade Idea Suggestions - Newser
Using economic indicators to assess Cybin Inc. potentialWall Street Watch & Risk Managed Trade Strategies - Newser
Pattern recognition hints at Cybin Inc. upsideWeekly Stock Report & Free High Return Stock Watch Alerts - Newser
Real time social sentiment graph for Cybin Inc.Volume Spike & Weekly Watchlist for Hot Stocks - Newser
Cybin receives Australian approval for EMBRACE study - TipRanks
Is Cybin Inc. a candidate for recovery playJuly 2025 Macro Moves & Intraday High Probability Alerts - Newser
Cybin Gains Australian Approval for EMBRACE Study in Major Depressive Disorder - TipRanks
Cybin Gets Approval for Major Depressive Disorder Treatment Study Evaluating CYB003 in Australia - MarketScreener
Cybin gets Australian approval for Embrace - AInvest
Cybin Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder - Business Wire
What does recent volatility data suggest for Cybin Inc.2025 Macro Impact & Free Safe Entry Trade Signal Reports - Newser
What momentum shifts mean for Cybin Inc.July 2025 Selloffs & AI Driven Price Predictions - Newser
Does Cybin Inc. fit your quant trading modelQuarterly Earnings Report & Weekly Sector Rotation Insights - Newser
Momentum divergence signals in Cybin Inc. chartJuly 2025 Technicals & AI Powered Buy/Sell Recommendations - Newser
Cybin Inc. stock momentum explainedIPO Watch & AI Driven Stock Reports - Newser
Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose - Quantisnow
Cybin Inc. recovery potential after sell offWeekly Trading Summary & AI Enhanced Trading Signals - Newser
Risk adjusted return profile for Cybin Inc. analyzedWeekly Market Summary & Safe Capital Growth Tips - Newser
Cybin Announces Shareholder Meeting Results and Strategic Developments - MSN
Can momentum traders help lift Cybin Inc.2025 Bull vs Bear & Free Long-Term Investment Growth Plans - Newser
Is Now a Good Time to Reenter Cybin Inc.Portfolio Gains Summary & Consistent Income Trade Ideas - mustnews.co.kr
Can Cybin Inc. Rally Enough to Break EvenStock Surge & AI Powered Buy and Sell Recommendations - classian.co.kr
Cybin Inc. Moves Into Bullish Territory Based on MACDEarnings Overview Summary & Fast Exit and Entry Strategy Plans - newsyoung.net
Key resistance and support levels for Cybin Inc.Quarterly Growth Report & Daily Oversold Stock Bounce Ideas - Newser
Cybin Inc. Reports Strong Shareholder Participation in 2025 Annual Meeting - citybuzz -
H.C. Wainwright reiterates Buy rating on Cybin stock, maintains $150 target - Investing.com
Cybin's Strategic Advancements and Financial Positioning Drive Buy Rating - AInvest
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Cybin Announces Results of Annual Meeting of Shareholders - FinancialContent
Cybin Inc. shares rise 2.17% after-hours following the Annual Meeting of Shareholders. - AInvest
Cybin Inc.'s Strategic Positioning in the Psychedelic Therapy Market: A Catalyst for Shareholder Value Creation - AInvest
Cybin’s Strategic Advancements and Financial Positioning Drive Buy Rating - TipRanks
Transcript : Cybin Inc.Shareholder/Analyst Call - MarketScreener
Why Cybin Inc. stock attracts strong analyst attentionJuly 2025 Final Week & Daily Profit Focused Screening - classian.co.kr
Cybin Posts Q1 2026 Loss of -$0.54 EPS; Market Reacts with Mixed Short-Term Optimism - AInvest
Using data tools to time your Cybin Inc. exit2025 Top Gainers & AI Enhanced Execution Alerts - Newser
Heatmap Data Shows High Activity in Cybin Inc. SectorRisk Management & Free Weekly Watchlist of Top Performers - newsyoung.net
How Cybin Inc. stock performs during market volatilityJuly 2025 Trends & Community Consensus Picks - Newser
Cybin Earnings Report (2026 Q1): Negative Net Income, Weak Margins, and Mixed Post-Earnings Market Signals - AInvest
Intrinsic Value of Cybin Inc. Stock: Is It Undervalued or Overvalued2025 Geopolitical Influence & AI Forecast for Swing Trade Picks - Newser
Top Risks to Consider Before Buying Cybin Inc. StockBond Market & Real-Time Market Sentiment Alerts - Newser
Earnings visualization tools for Cybin Inc.Weekly Stock Summary & Weekly High Potential Alerts - Newser
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin Inc. Reports Q2 2025 Financial Results with Asset Growth - MSN
What’s next for Cybin Inc. stock priceQuarterly Earnings Report & Expert Curated Trade Ideas - Newser
Cybin reports Q1 results - MSN
Is Cybin Inc. stock overvalued or fairly pricedBreakout Watch & Reliable Price Breakout Signals - newsyoung.net
Psychedelic Stock Earnings: atai Life Sciences, Cybin Report Q1 Results - AInvest
Which companies are leading the development of psychedelic wellness products? - AInvest
Cybin Inc. Common Shares (NYSE:CYBN) Stock Quote - FinancialContent
Trend Reversal Possible in Cybin Inc. Charts IndicateWeekly Investment Summary & Fast Entry and Exit Trade Plans - sundaytimes.kr
Psychedelic: atai Life Sciences, Cybin report earnings results - TipRanks
MACD Cross Could Confirm Trend in Cybin Inc.2025 Technical Overview & AI Forecast for Swing Trade Picks - thegnnews.com
Cybin Reports Q1 FY26 Financials, Advances Clinical Programs, and Secures $50M Financing Agreement. - AInvest
0.95%
0.90%
Kapitalisierung:
|
Volumen (24h):